HIV Prevention Study for High-Risk Individuals in Lesotho
Part of Immune system & allergy, Infections clinical trials.
This study tests whether combining different HIV prevention methods (like preventive medications and counseling) can better protect people at high risk of HIV infection in Lesotho. You may qualify if you're already in the ComBaCaL study, are HIV-negative, and have had recent potential HIV exposure or ongoing risk factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already enrolled in the ComBaCaL cohort study in Lesotho
- You weigh at least 35 kg (about 77 pounds)
- Your most recent HIV test came back negative
- Your potential HIV exposure happened between 72 hours and 4 weeks ago, or you have ongoing high-risk situations
- You have at least one behavioral risk factor for HIV (such as unprotected sex, multiple partners, or known exposure to someone with HIV)
- You do not have severe kidney disease or known allergies to HIV prevention medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
Hear when a new Human Immunodeficiency Virus (HIV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.